<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127728">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01879475</url>
  </required_header>
  <id_info>
    <org_study_id>CT001</org_study_id>
    <nct_id>NCT01879475</nct_id>
  </id_info>
  <brief_title>Safety and Performance of 032-11 Haemostat in Cardiac and Thoracic Aortic Surgery</brief_title>
  <official_title>Prospective, Randomised, Controlled Investigation Comparing the Safety and Performance of 032-11 Surgical Haemostat With FLOSEALÂ® Haemostatic Matrix in Cardiac Surgery and Thoracic Aortic Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtrade</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Clinical Trial Company, Knutsford, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtrade</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effectiveness objective of this study is to evaluate whether 032-11 is non-inferior to
      Floseal as an adjunct to achieving haemostasis during surgical procedures involving cardiac
      and aortic thoracic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Haemostasis success</measure>
    <time_frame>Intra-operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients achieving haemostasis success following the first application of compression.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>C.Surgical Procedure; Cardiac</condition>
  <condition>Haemorrhage.</condition>
  <arm_group>
    <arm_group_label>032-11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>032-11 topical haemostat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Floseal (R)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Floseal(R) topical haemostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>032-11</intervention_name>
    <description>Topical haemostat</description>
    <arm_group_label>032-11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Floseal (R)</intervention_name>
    <description>Topical haemostat</description>
    <arm_group_label>Floseal (R)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must be equal or greater than 18 years old

          -  The patient must have elective or non-elective urgent cardiac surgery or thoracic
             aortic surgery

          -  The patient must have no childbearing potential or have a negative serum or urine
             pregnancy test within 7 days of the planned surgery or in the opinion of the
             Investigator performs adequate contraception

          -  The patient is willing and able to be contacted for the follow-up visit at 6- 8 weeks

          -  The patient must provide written informed consent using a form that is reviewed and
             approved by the IEC

        Exclusion Criteria:

          -  The patient is currently enrolled in this or another investigational device or drug
             trial that has not completed the required follow up period.

          -  The patient has a known hypersensitivity to materials of bovine origin

          -  The patient does not wish to receive materials of bovine or shellfish origin for any
             reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Millner, MD FRCS</last_name>
    <role>Study Chair</role>
    <affiliation>Blackpool Victoria Hospital NHS trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Farmer</last_name>
    <phone>+44 1270 500 019</phone>
    <email>saraandpete.farmer@virgin.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>June Gladman, PhD</last_name>
    <phone>+44 1270 500 019</phone>
    <email>june.gladman@medtrade.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <state>East Yorkshire</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mahmoud Loubani, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 13, 2013</lastchanged_date>
  <firstreceived_date>June 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
